IRWD News and Press, Ironwood Pharmaceuticals Inc. From 02/02/23

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 16, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (...

Summary Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality. Fast facts on GNOM. 10 stocks cheaper than their peers in January. This monthly article...

The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with this event. For further details see: Ironwood Pharmaceuticals (IRWD) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow

– sNDA submitted to U.S. FDA in December 2022 seeking approval of a new indication of LINZESS® (linaclotide) for functional constipation in children and adolescents 6 to 17 years of age – – Expects high single-digit LINZESS® EUTRx prescription de...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time at The Westin St. Fran...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 34 th Annual Healthcare Conference on Tuesday, November 29, 2022 at 4:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will be acc...

Summary The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Healthcare equipment and life science tools are overvalued by about 25% regarding the same metrics. Fast facts on IDNA. 10 stocks cheaper than their peers in No...

Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2022 Results Conference Call November 3, 2022 08:30 AM ET Company Participants Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Matt Roache - Director ...

Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q3 Non-GAAP EPS of $0.28 beats by $0.01 . Revenue of $108.64M (+4.7% Y/Y) misses by $1.76M . Reaffirms FY22 Guidance: In 2022, Ironwood continues to expect: U.S. LINZESS Net Sales Growth&#x...

– LINZESS ® (Iinaclotide) EUTRx prescription demand growth in Q3 2022 increased 10% year-over-year – – Ironwood and its partner, AbbVie, plan to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FD...